Nebulized tobramycin in the treatment of adult cf pulmonary exacerbations

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 27, Issue 4, 2014, Pages 299-305

  Al Aloul, Mohamed ^a   Nazareth, Dilip ^b   Walshaw, Martin ^b  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b LIVERPOOL HEART AND CHEST HOSPITAL   (United Kingdom)

Author keywords

cystic fibrosis; nebulized tobramycin; renal sparing

Indexed keywords

COLISTIN; TOBRAMYCIN; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BLOOD TOXICITY; BRONCHOSPASM; CLINICAL ARTICLE; CONJUNCTIVAL HYPEREMIA; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DISEASE EXACERBATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FORCED EXPIRATORY VOLUME; HEMOPTYSIS; HOARSENESS; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; KIDNEY TUBULE DAMAGE; LUNG DISEASE; MALE; NEBULIZER; PARESTHESIA; PATIENT SATISFACTION; PHARYNGITIS; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY DISTRESS; RHINORRHEA; SPIROMETRY; TINNITUS; YOUNG ADULT; BLOOD; COMPARATIVE STUDY; DISEASE COURSE; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; KIDNEY; LUNG; MICROBIOLOGY; PATHOPHYSIOLOGY; PILOT STUDY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPUTUM; TIME; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CROSS-OVER STUDIES; CYSTIC FIBROSIS; DISEASE PROGRESSION; ENGLAND; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY; LUNG; MALE; NEBULIZERS AND VAPORIZERS; PILOT PROJECTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS; SPUTUM; TIME FACTORS; TOBRAMYCIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84905485932     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2013.1055     Document Type: Article

References (35)

1. Al-Aloul M, Miller H, Alapati S, Stockton PA, Ledson MJ, and Walshaw MJ: Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol. 2005;39:15-20.
2. Yuen CT, Price RG, Chattagoon L, Richardson AC, and Praill PF: Colorimetric assays for N-acetyl-beta-D-glucosaminidase and beta-D-galactosidase in human urine using newly-developed omega-nitrostyryl substrates. Clin Chim Acta. 1982;124:195-204.
3. Marchewka Z, and Dlugosz A: Enzymes in urine as markers of nephrotoxicity of cytostatic agents and aminoglycoside antibiotics. Int Urol Nephrol. 1998;30:339-348.
4. Jung K, and Scholz D: An optimized assay of alanine aminopeptidase activity in urine. Clin Chem. 1980;26:1251-1254.
5. Bethea M, and Forman DT: Beta 2-microglobulin: its significance and clinical usefulness. Ann Clin Lab Sci. 1990;20: 163-168.
6. Makino H, Hayashi Y, Shikata K, Hirata K, Akiyama K, Ogura T, Obata K, and Ota Z: Urinary detection of type IV collagen and its increase in glomerulonephritis. Res Commun Mol Pathol Pharmacol. 1995;88:215-223.
7. Okonogi H, Nishimura M, Utsunomiya Y, Hamaguchi K, Tsuchida H, Miura Y, Suzuki S, Kawamura T, Hosoya T, and Yamada K: Urinary type IV collagen excretion reflects renal morphological alterations and type IV collagen expression in patients with type 2 diabetes mellitus. Clin Nephrol. 2001;55:357-364.
8. Herrmann G, Yang L, Wu H, Song Z, Wang H, Hoiby N, Ulrich M, Molin S, Riethmüller J, and Döring G: Colistintobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis. 2010;202:1585-1592.
9. Gibson RL, Emerson J, Mayer-Hamblett N, Burns JL, McNamara S, Accurso FJ, Konstan MW, Chatfield BA, Retsch-Bogart G, Waltz DA, Acton J, Zeitlin P, Hiatt P, Moss R, Williams J, and Ramsey BW: Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosis. Pediatr Pulmonol. 2007;42:610-623.
10. Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, and Mazurek H: A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study. Paediatr Drugs. 2007;9 Suppl 1:21-31.
11. Britto MT, Kotagal UR, Hornung RW, Atherton HD, Tsevat J, and Wilmott RW: Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest. 2002;121:64-72.
12. Jarad NA, Higgs S, Jeffcote T, and Giles K: Factors associated with reduced FEV1 in adult patients with cystic fibrosis in a relatively affluent area. Chronic Respir Dis. 2005;2:133-137.
13. LiPuma JJ: Microbiological and immunologic considerations with aerosolized drug delivery. Chest. 2001;120:118S-123S.
14. Moss RB: Administration of aerosolized antibiotics in cystic fibrosis patients. Chest. 2001;120:107S-113S.
15. Mendelman PM, Smith AL, Levy J, Weber A, Ramsey B, and Davis RL: Aminoglycoside penetration, inactivation, and efficacy in cystic fibrosis sputum. Am Rev Respir Dis. 1985; 132:761-765.
16. Lenoir G, Antypkin YG, Miano A, Moretti P, Zanda M, Varoli G, Monici Preti PA, and Aryayev NL: Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Paediatr Drugs. 2007;9 Suppl 1:11-20.
17. Anderson GG, Moreau-Marquis S, Stanton BA, and O'Toole GA: In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells. Infect Immun. 2008;76:1423-1433.
18. Eisenberg J, Pepe M, Williams-Warren J, Vasiliev M, Montgomery AB, Smith AL, and Ramsey BW: A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group. Chest. 1997;111:955-962.
19. Weber A, Morlin G, Cohen M, Williams-Warren J, Ramsey B, and Smith A: Effect of nebulizer type and antibiotic concentration on device performance. Pediatr Pulmonol. 1997;23:249-260.
20. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, Vasiljev KM, Borowitz D, Bowman CM, Marshall BC, Marshall S, and Smith AL: Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:23-30.
21. Burns JL, Van Dalfsen JM, Shawar RM, Otto KL, Garber RL, Quan JM, Montgomery AB, Albers GM, Ramsey BW, and Smith AL: Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis. 1999;179:1190-1196.
22. Gibson RL, Emerson J, McNamara S, Burns JL, Rosenfeld M, Yunker A, Hamblett N, Accurso F, Dovey M, Hiatt P, Konstan MW, Moss R, Retsch-Bogart G, Wagener J, Waltz D, Wilmott R, Zeitlin PL, and Ramsey B: Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med. 2003;167:841-849.
23. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, and Ramsey BW: Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219-226.
24. Alothman GA, Alsaadi MM, Ho BL, Ho SL, Dupuis A, Corey M, and Coates AL: Evaluation of bronchial constriction in children with cystic fibrosis after inhaling two different preparations of tobramycin. Chest. 2002;122:930-934.
25. Smyth A, Lewis S, Bertenshaw C, Choonara I, McGaw J, and Watson A: Case-control study of acute renal failure in patients with cystic fibrosis in the UK. Thorax. 2008;63:532-535.
26. Smyth A, Tan KH, Hyman-Taylor P, Mulheran M, Lewis S, Stableforth D, and Knox A; TOPIC Study Group: Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis - the TOPIC study: a randomised controlled trial. Lancet. 2005;365:573-578.
27. Al-Aloul M, Jackson M, Bell G, Ledson M, and Walshaw M: Comparison of methods of assessment of renal function in cystic fibrosis (CF) patients. J Cyst Fibros. 2007;6:41-47.
28. Reed MD, Vermeulen MW, Stern RC, Cheng PW, Powell SH, and Boat TF: Are measurements of urine enzymes useful during aminoglycoside therapy? Pediatr Res. 1981;15:1234-1239.
29. Steinkamp G, Lutge M, Wurster U, Schulz-Baldes JG, Grone HJ, and Ehrich JH: Renal function in cystic fibrosis: proteinuria and enzymuria before and after tobramycin therapy. Eur J Pediatr. 1986;145:526-531.
30. Godson C, Ryan MP, O'Halloran D, Bourke S, Brady HR, and FitzGerald MX: Investigation of aminoglycoside nephrotoxicity in cystic fibrosis patients. Scand J Gastroenterol Suppl. 1988;143:70-73.
31. Ring E, Eber E, Erwa W, and Zach MS: Urinary N-acetyl-b- D-glucosaminidase activity in patients with cystic fibrosis on long-term gentamicin inhalation. Arch Dis Child. 1998; 78:540-543.
32. Pannu N, and Nadim MK: An overview of drug-induced acute kidney injury. Crit Care Med. 2008;36:S216-S223.
33. Mingeot-Leclercq MP, and Tulkens PM: Aminoglycosides: nephrotoxicity. Antimicrobial Agents Chemother. 1999;43: 1003-1012.
34. Pedersen SS, Jensen T, Osterhammel D, and Osterhammel P: Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrobial Agents Chemother. 1987;31:594-599.
35. Hoffmann IM, Rubin BK, Iskandar SS, Schechter MS, Nagaraj SK, and Bitzan MM: Acute renal failure in cystic fibrosis: association with inhaled tobramycin therapy. Pediatr Pulmonol. 2002;34:375-377.